Aurinia Pharmaceuticals Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Board elections ensure company leadership is chosen by owners; auditor approval maintains financial trust and transparency.
Major deal adds new drug assets and scientific talent; price per share shows how much Aurinia paid for the company.
Quarterly earnings show if the company is making money and growing; investors use this to track company health.
Major acquisition deal signals company growth strategy; $6.955 cash plus contingent payments shows deal structure.
New leadership changes can affect company direction; Tang has deep pharma and investment experience in the field.
Annual earnings reveal total revenue, profits and losses; shows whether company achieved its yearly business goals.
Stocky reads Aurinia Pharmaceuticals Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Aurinia Pharmaceuticals Inc.'s most recent tracked filing was a 8-K on 4 Jun 2026: Shareholders elect five directors; approve auditor and pay plan.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.